The American Journal of Managed Care

Trastuzumab Deruxtecan Brings Encouraging Responses in HER2-Expressing Cancers Across Multiple Tumor Types

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need. Trastuzumab deruxtecan, already used in to treat patients with breast, ...
Business Wire

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 phase 2 trial and supported by data from additional trials including TROPION-Lung01 Previously submitted BLA based on ...
Monthly Prescribing Reference

Neoadjuvant Trastuzumab Deruxtecan Promising in High-Risk, HER2+ Early Breast Cancer

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 trial ...
The American Journal of Managed Care

FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
Oncology Nurse Advisor

Enhertu Gains Two HER2-Positive Early Breast Cancer Indications

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.
Business Wire

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Initial results from the TROPION-Lung04 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, an ...
Medical Xpress

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug ...
Monthly Prescribing Reference

Trastuzumab Deruxtecan + Pertuzumab Under Review For First-Line HER2+ Metastatic Breast Cancer

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...
Cure Today

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage and higher ...
Yahoo Finance

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...